Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has disclosed that it has received authorization from the European Commission to start the treatment of patients ages six years and older suffering from cystic fibrosis. The patients will get the treatment with SYMKEVI in combination with KALYDECO. This authorization has given a new option to patients. This therapy will pinpoint the basic cause of CF.
The treatment will be accessible to qualified patients in Germany and other countries that inked an agreement with vertex. Vertex has already received consent for the treatment of patients in Europe. VRTX’s main goal is to give therapy to all patients with CF.